Posted by Michael Wonder on 29 Mar 2018
Mylan introduces Symfi triple combo once-daily HIV treatment in the U.S.
28 March 2018 - All ARV regimens are being offered at a significant discount to the price of competing products to bring cost savings to the $20 billion U.S. ARV market.
Mylan today announced that it will introduce in the U.S. a third cost-saving HIV combination. The U.S. FDA approved Symfi (efavirenz, lamivudine and tenofovir disoproxil fumarate) 600 mg/300 mg/300 mg tablets, a once-daily, single-tablet regimen, indicated as a complete regimen for the treatment of human immunodeficiency virus type 1 infection in adult and paediatric patients weighing at least 40 kg.
Following FDA approval, Mylan launched Symfi Lo earlier in March. It expects Cimduo and Symfi to launch in the second quarter of 2018.
